Welcome to our dedicated page for Compass Therapeutics SEC filings (Ticker: CMPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compass Therapeutics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD updates, clinical data presentations and other material events related to tovecimig and the broader antibody pipeline.
The company’s definitive proxy materials cover annual meeting matters, director elections and stockholder voting procedures. Filing disclosures also address governance, equity compensation, capital-structure matters, cash resources, clinical and regulatory risk areas, and the public-company controls associated with a Nasdaq-listed development-stage biotechnology issuer.
Compass Therapeutics, Inc. is offering 33,290,000 shares of common stock and, in lieu of shares to certain investors, pre-funded warrants to purchase 6,710,000 shares. The public offering price is $3.00 per share (pre-funded warrants at $2.9999), with underwriting discounts of $0.18 per share. Net proceeds are estimated at approximately $112.5 million (or about $129.5 million if the underwriters fully exercise their option to buy an additional 6,000,000 shares). The company reported $100.9 million in cash as of June 30, 2025 and states these proceeds, together with existing cash, are expected to fund operations into 2028. Purchasers will face immediate dilution (disclosed as $1.85 per share in one illustration and $1.80 per share in a pro forma table). There is no public market for the pre-funded warrants and exercise limitations (default 4.99% beneficial ownership cap) apply. The common stock trades on Nasdaq under CMPX.
MPM BioImpact LLC reports beneficial ownership of 5,622,505 shares of Compass Therapeutics common stock, equal to 4.1% of the class. The filing states the reporting person has sole voting power and sole dispositive power over the reported shares and identifies the filer as an investment adviser (IA). The filer certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer. Because the stake is below 5%, this Schedule 13G/A reflects a passive, non-control disclosure under the Exchange Act.
Compass Therapeutics, Inc. (CMPX) has filed a preliminary prospectus supplement offering shares of common stock and, in lieu of shares for some investors, pre-funded warrants to purchase common stock. The company’s common stock trades on The Nasdaq Capital Market under the symbol CMPX, with the last reported sale price of $3.34 on August 11, 2025. The pre-funded warrants are not listed and are exercisable at $0.0001 per share; their public purchase price equals the public offering price less $0.0001.
Compass is a clinical-stage oncology company with lead candidates including tovecimig (CTX-009) (DLL4/VEGF-A bispecific), CTX-471 (CD-137 agonist), CTX-8371 (PD-1/PD-L1 bispecific) and CTX-10726 in IND-enabling studies. As of June 30, 2025, the company reported $100.9 million in cash and cash equivalents and states that combined with the proceeds of this offering it expects those resources will be sufficient to fund operations into 2028.
The prospectus highlights investor risks including significant market volatility, potential dilution (historical net tangible book value was $93 million, or $0.67 per share as of June 30, 2025), the lack of a trading market for the pre-funded warrants, exercise ownership limits (generally 4.99% or 9.99%, adjustable up to 19.99% with notice) and that Compass is an emerging growth company and a smaller reporting company.
Compass Therapeutics is a clinical-stage oncology biotech developing antibody-based therapies focused on angiogenesis and immune-oncology pathways. Its lead candidate, tovecimig (DLL4 x VEGF-A), met the study's primary endpoint with a 17.1% overall response rate versus 5.3% for paclitaxel alone (p=0.031), and independent Data Monitoring Committee reviews recommended continuation. The company reports fewer overall survival events than modeled, with pooled OS analyses now expected in Q1 2026.
Financially, Compass recorded a net loss of $19.9 million for the quarter and $36.5 million for the six months, with an accumulated deficit of $401.2 million. Cash, cash equivalents and marketable securities totaled $101 million, which management expects will fund operations into 2027. Research and development expenses rose substantially, driven by increased manufacturing costs for tovecimig and CTX-10726, and the company reported accrued manufacturing obligations including $3.6 million minimum contractual commitments.
Compass Therapeutics furnished a Current Report on Form 8-K announcing that it issued a press release with financial results for the quarter and six months ended June 30, 2025. The press release is included as Exhibit 99.1. The company also furnished the slides presented on its second quarter earnings call as Exhibit 99.2 and its August 2025 corporate presentation as Exhibit 99.3. The filing states that the materials in Item 7.01 (including Exhibit 99.2) are being furnished and not filed, and thus are not subject to Section 18 liabilities or automatically incorporated by reference in other filings. The report discloses the company's common stock trades under the symbol CMPX on the NASDAQ Capital Market. No financial figures are included within the 8-K itself; detailed results are provided in the furnished press release.